Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that despite morbidity associated with hypertension, almost 65% of newly diagnosed patients do not receive drug treatment in the first 360 days of their diagnosis.

"We believe that physicians are prescribing lifestyle modifications such as diet and exercise to the majority of these patients before initiating drug treatment," said Jeremy Goldman, M.D., analyst at Decision Resources. "This level of non-pharmacological treatment is contrary to the advice of thought leaders who only recommend a trial of two to three months with lifestyle interventions."

The report entitled Treatment Algorithms in Hypertension also reveals that surveyed physicians consider beta blockers to be effective in lowering the risk of the cardiovascular complications of hypertension. Seventy-three percent of primary care physicians (PCPs) and 81% of cardiologists consider this benefit a reason for choosing AstraZeneca's Toprol XL over Pfizer's Norvasc. Beta blockers are currently prescribed in 24.3 percent of new patients compared to only 9.9 percent of new patients who are prescribed a calcium-channel blocker

About Treatment Algorithm Insight Series

Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics® to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.

For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides:

  -- Summary of U.S. medical practice based on interviews with leading      experts in the field   -- Qualitative diagnosis/referral/treatment algorithm for the United      States   -- Drug usage by lines of therapy (1st, 2nd, 3rd line)   -- Discussion of key freeform combinations by lines of therapy   -- Product share (class and specific compound level) within each line of      therapy (1st, 2nd, 3rd line)   -- Progression of therapy from key 1st line products   -- Pathway to key therapies from previous therapies   -- Qualitative analysis of 2-year forecast incorporating upcoming      launches, changes in reimbursement, etc.    About Decision Resources 

Decision Resources, Inc., ( ) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Substantial Growth Forecasted for China's Colorectal Cancer Drug Market

View Now